BofA moved to No Rating from Underperform on Sage Therapeutics (SAGE) after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals (SUPN) for a total up to $12 per share. Sage shares are no longer trading on fundamentals given the deal announcement, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
- Video: Sarepta, Hinge Health among major pre-market movers
- SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals